Literature DB >> 20465658

Prevention and treatment of systemic glucocorticoid side effects.

Siamak Moghadam-Kia1, Victoria P Werth.   

Abstract

BACKGROUND: Systemic glucocorticoids are used in dermatologic practice for various diseases including connective tissue disorders, bullous diseases, and many other dermatologic conditions. Patients with these diseases are at times treated with long-term courses of glucocorticoids, which place them at increased risk for glucocorticoid-induced side effects. Therefore, dermatologists must be knowledgeable of risks related to glucocorticoid use and be familiar with guidelines to manage them.
OBJECTIVE: To provide an update of recent advances in the prevention and treatment of major glucocorticoid-induced side effects.
METHODS: Review of the literature.
RESULTS: Data regarding the prevention and treatment of glucocorticoid-induced side effects are presented.
CONCLUSION: This review should help dermatologists optimally manage and prevent glucocorticoid-induced side effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20465658      PMCID: PMC2872100          DOI: 10.1111/j.1365-4632.2009.04322.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  75 in total

Review 1.  The science and therapy of glucocorticoid-induced bone loss.

Authors:  N E Lane; B Lukert
Journal:  Endocrinol Metab Clin North Am       Date:  1998-06       Impact factor: 4.741

Review 2.  Bisphosphonates: mechanisms of action.

Authors:  G A Rodan; H A Fleisch
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

Review 3.  Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention.

Authors:  T K LaPier
Journal:  J Cardiopulm Rehabil       Date:  1997 Mar-Apr       Impact factor: 2.081

Review 4.  Neuromuscular sequelae of critical illness.

Authors:  Nicola Latronico; Indrit Shehu; Elisa Seghelini
Journal:  Curr Opin Crit Care       Date:  2005-08       Impact factor: 3.687

5.  Risk factors for hydrocortisone myopathy in acute severe asthma.

Authors:  C D Shee
Journal:  Respir Med       Date:  1990-05       Impact factor: 3.415

6.  Histopathologic study of veins in steroid treated rabbits.

Authors:  T Nishimura; T Matsumoto; M Nishino; K Tomita
Journal:  Clin Orthop Relat Res       Date:  1997-01       Impact factor: 4.176

7.  Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip.

Authors:  R S Weinstein; R W Nicholas; S C Manolagas
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

8.  Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.

Authors:  J D Ringe; A Dorst; H Faber; K Ibach; J Preuss
Journal:  Rheumatology (Oxford)       Date:  2003-04-16       Impact factor: 7.580

9.  Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis.

Authors:  L M Buckley; E S Leib; K S Cartularo; P M Vacek; S M Cooper
Journal:  J Rheumatol       Date:  1995-06       Impact factor: 4.666

10.  Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.

Authors:  J D Ringe; A Dorst; H Faber; K Ibach; F Sorenson
Journal:  Osteoporos Int       Date:  2003-08-28       Impact factor: 4.507

View more
  64 in total

1.  Glucocorticoids suppress selected components of the senescence-associated secretory phenotype.

Authors:  Remi-Martin Laberge; Lili Zhou; Melissa R Sarantos; Francis Rodier; Adam Freund; Peter L J de Keizer; Su Liu; Marco Demaria; Yu-Sheng Cong; Pankaj Kapahi; Pierre-Yves Desprez; Robert E Hughes; Judith Campisi
Journal:  Aging Cell       Date:  2012-04-17       Impact factor: 9.304

2.  Therapeutic Dilemma of Refractory Erythema Nodosum Leprosum.

Authors:  Jianyu Zhu; Degang Yang; Chao Shi; Zhichun Jing
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

Review 3.  Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.

Authors:  Kirk N Campbell; James A Tumlin
Journal:  Am J Nephrol       Date:  2018-05-31       Impact factor: 3.754

Review 4.  Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly.

Authors:  Martin Soubrier; Clement Lahaye; Zuzana Tatar
Journal:  Drugs Aging       Date:  2018-05       Impact factor: 3.923

5.  The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemia.

Authors:  Lauren C Daniel; Yimei Li; Jacqueline D Kloss; Anne F Reilly; Lamia P Barakat
Journal:  Support Care Cancer       Date:  2016-04-23       Impact factor: 3.603

6.  A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.

Authors:  E-J Choi; B-J Jung; S-H Lee; H-S Yoo; E-A Shin; H-J Ko; S Chang; S-Y Kim; S-M Jeon
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

Review 7.  Diet and dermatology: the role of dietary intervention in skin disease.

Authors:  Rajani Katta; Samir P Desai
Journal:  J Clin Aesthet Dermatol       Date:  2014-07

8.  Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.

Authors:  Andreas Kronbichler; Paul König; Martin Busch; Gunter Wolf; Gert Mayer; Michael Rudnicki
Journal:  Wien Klin Wochenschr       Date:  2013-04-27       Impact factor: 1.704

9.  Forkhead box A3 mediates glucocorticoid receptor function in adipose tissue.

Authors:  Xinran Ma; Lingyan Xu; Elisabetta Mueller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-08       Impact factor: 11.205

10.  Charge based intra-cartilage delivery of single dose dexamethasone using Avidin nano-carriers suppresses cytokine-induced catabolism long term.

Authors:  A G Bajpayee; M A Quadir; P T Hammond; A J Grodzinsky
Journal:  Osteoarthritis Cartilage       Date:  2015-07-26       Impact factor: 6.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.